Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 39

1.

Quercetin Targets hnRNPA1 to Overcome Enzalutamide Resistance in Prostate Cancer Cells.

Tummala R, Lou W, Gao AC, Nadiminty N.

Mol Cancer Ther. 2017 Dec;16(12):2770-2779. doi: 10.1158/1535-7163.MCT-17-0030. Epub 2017 Jul 20.

2.

Niclosamide and Bicalutamide Combination Treatment Overcomes Enzalutamide- and Bicalutamide-Resistant Prostate Cancer.

Liu C, Armstrong CM, Lou W, Lombard AP, Cucchiara V, Gu X, Yang JC, Nadiminty N, Pan CX, Evans CP, Gao AC.

Mol Cancer Ther. 2017 Aug;16(8):1521-1530. doi: 10.1158/1535-7163.MCT-16-0912. Epub 2017 May 12.

3.

Lin28 induces resistance to anti-androgens via promotion of AR splice variant generation.

Tummala R, Nadiminty N, Lou W, Evans CP, Gao AC.

Prostate. 2016 Apr;76(5):445-55. doi: 10.1002/pros.23134. Epub 2015 Dec 30.

4.

NF-κB2/p52:c-Myc:hnRNPA1 Pathway Regulates Expression of Androgen Receptor Splice Variants and Enzalutamide Sensitivity in Prostate Cancer.

Nadiminty N, Tummala R, Liu C, Lou W, Evans CP, Gao AC.

Mol Cancer Ther. 2015 Aug;14(8):1884-95. doi: 10.1158/1535-7163.MCT-14-1057. Epub 2015 Jun 8.

5.

Intracrine Androgens and AKR1C3 Activation Confer Resistance to Enzalutamide in Prostate Cancer.

Liu C, Lou W, Zhu Y, Yang JC, Nadiminty N, Gaikwad NW, Evans CP, Gao AC.

Cancer Res. 2015 Apr 1;75(7):1413-22. doi: 10.1158/0008-5472.CAN-14-3080. Epub 2015 Feb 3.

6.

Interleukin-6 induces neuroendocrine differentiation (NED) through suppression of RE-1 silencing transcription factor (REST).

Zhu Y, Liu C, Cui Y, Nadiminty N, Lou W, Gao AC.

Prostate. 2014 Aug;74(11):1086-94. doi: 10.1002/pros.22819. Epub 2014 May 12.

PMID:
24819501
7.

Niclosamide inhibits androgen receptor variants expression and overcomes enzalutamide resistance in castration-resistant prostate cancer.

Liu C, Lou W, Zhu Y, Nadiminty N, Schwartz CT, Evans CP, Gao AC.

Clin Cancer Res. 2014 Jun 15;20(12):3198-3210. doi: 10.1158/1078-0432.CCR-13-3296. Epub 2014 Apr 16. Erratum in: Clin Cancer Res. 2017 Jan 1;23 (1):323.

8.

Upregulation of glucose metabolism by NF-κB2/p52 mediates enzalutamide resistance in castration-resistant prostate cancer cells.

Cui Y, Nadiminty N, Liu C, Lou W, Schwartz CT, Gao AC.

Endocr Relat Cancer. 2014 May 6;21(3):435-42. doi: 10.1530/ERC-14-0107. Print 2014 Jun.

9.

RhoGDIα downregulates androgen receptor signaling in prostate cancer cells.

Zhu Y, Liu C, Tummala R, Nadiminty N, Lou W, Gao AC.

Prostate. 2013 Nov;73(15):1614-22. doi: 10.1002/pros.22615. Epub 2013 Aug 6.

10.

Inhibition of ABCB1 expression overcomes acquired docetaxel resistance in prostate cancer.

Zhu Y, Liu C, Nadiminty N, Lou W, Tummala R, Evans CP, Gao AC.

Mol Cancer Ther. 2013 Sep;12(9):1829-36. doi: 10.1158/1535-7163.MCT-13-0208. Epub 2013 Jul 16.

11.

Lin28 promotes growth of prostate cancer cells and activates the androgen receptor.

Tummala R, Nadiminty N, Lou W, Zhu Y, Gandour-Edwards R, Chen HW, Evans CP, Gao AC.

Am J Pathol. 2013 Jul;183(1):288-95. doi: 10.1016/j.ajpath.2013.03.011.

12.

NF-κB2/p52 induces resistance to enzalutamide in prostate cancer: role of androgen receptor and its variants.

Nadiminty N, Tummala R, Liu C, Yang J, Lou W, Evans CP, Gao AC.

Mol Cancer Ther. 2013 Aug;12(8):1629-37. doi: 10.1158/1535-7163.MCT-13-0027. Epub 2013 May 22.

13.

Functional p53 determines docetaxel sensitivity in prostate cancer cells.

Liu C, Zhu Y, Lou W, Nadiminty N, Chen X, Zhou Q, Shi XB, deVere White RW, Gao AC.

Prostate. 2013 Mar;73(4):418-27. doi: 10.1002/pros.22583. Epub 2012 Sep 19.

14.

MicroRNA let-7c is downregulated in prostate cancer and suppresses prostate cancer growth.

Nadiminty N, Tummala R, Lou W, Zhu Y, Shi XB, Zou JX, Chen H, Zhang J, Chen X, Luo J, deVere White RW, Kung HJ, Evans CP, Gao AC.

PLoS One. 2012;7(3):e32832. doi: 10.1371/journal.pone.0032832. Epub 2012 Mar 30.

15.

MicroRNA let-7c suppresses androgen receptor expression and activity via regulation of Myc expression in prostate cancer cells.

Nadiminty N, Tummala R, Lou W, Zhu Y, Zhang J, Chen X, eVere White RW, Kung HJ, Evans CP, Gao AC.

J Biol Chem. 2012 Jan 6;287(2):1527-37. doi: 10.1074/jbc.M111.278705. Epub 2011 Nov 28.

16.

Mechanisms of persistent activation of the androgen receptor in CRPC: recent advances and future perspectives.

Nadiminty N, Gao AC.

World J Urol. 2012 Jun;30(3):287-95. doi: 10.1007/s00345-011-0771-3. Epub 2011 Oct 19. Review.

PMID:
22009116
17.

Andrographolide targets androgen receptor pathway in castration-resistant prostate cancer.

Liu C, Nadiminty N, Tummala R, Chun JY, Lou W, Zhu Y, Sun M, Evans CP, Zhou Q, Gao AC.

Genes Cancer. 2011 Feb;2(2):151-9. doi: 10.1177/1947601911409744.

18.

RhoGDIα suppresses growth and survival of prostate cancer cells.

Zhu Y, Tummala R, Liu C, Nadiminty N, Lou W, Evans CP, Zhou Q, Gao AC.

Prostate. 2012 Mar;72(4):392-8. doi: 10.1002/pros.21441. Epub 2011 Jun 16.

19.

Inhibition of Stat3 activation by sanguinarine suppresses prostate cancer cell growth and invasion.

Sun M, Liu C, Nadiminty N, Lou W, Zhu Y, Yang J, Evans CP, Zhou Q, Gao AC.

Prostate. 2012 Jan;72(1):82-9. doi: 10.1002/pros.21409. Epub 2011 May 2.

20.

Andrographolide, an herbal medicine, inhibits interleukin-6 expression and suppresses prostate cancer cell growth.

Chun JY, Tummala R, Nadiminty N, Lou W, Liu C, Yang J, Evans CP, Zhou Q, Gao AC.

Genes Cancer. 2010 Aug;1(8):868-76. doi: 10.1177/1947601910383416.

21.

Sanguinarine suppresses prostate tumor growth and inhibits survivin expression.

Sun M, Lou W, Chun JY, Cho DS, Nadiminty N, Evans CP, Chen J, Yue J, Zhou Q, Gao AC.

Genes Cancer. 2010 Mar;1(3):283-92. doi: 10.1177/1947601910368849.

22.

The N-terminal kinase suppressor of Ras complex has a weak nucleoside diphosphate kinase activity.

Yang X, You J, Luo W, Yue J, Ma L, Xiao W, Zhu D, Wu Z, Wang D, Nadiminty N, Gao AC, Zhou Q.

Thorac Cancer. 2010 Sep;1(3):109-115. doi: 10.1111/j.1759-7714.2010.00020.x.

23.

Aberrant activation of the androgen receptor by NF-kappaB2/p52 in prostate cancer cells.

Nadiminty N, Lou W, Sun M, Chen J, Yue J, Kung HJ, Evans CP, Zhou Q, Gao AC.

Cancer Res. 2010 Apr 15;70(8):3309-19. doi: 10.1158/0008-5472.CAN-09-3703. Epub 2010 Apr 13.

24.

Microarray analysis reveals potential target genes of NF-kappaB2/p52 in LNCaP prostate cancer cells.

Nadiminty N, Dutt S, Tepper C, Gao AC.

Prostate. 2010 Feb 15;70(3):276-87. doi: 10.1002/pros.21062.

PMID:
19827050
25.

Interleukin-6 regulates androgen synthesis in prostate cancer cells.

Chun JY, Nadiminty N, Dutt S, Lou W, Yang JC, Kung HJ, Evans CP, Gao AC.

Clin Cancer Res. 2009 Aug 1;15(15):4815-22. doi: 10.1158/1078-0432.CCR-09-0640. Epub 2009 Jul 28.

26.

Interleukin-4 activates androgen receptor through CBP/p300.

Lee SO, Chun JY, Nadiminty N, Lou W, Feng S, Gao AC.

Prostate. 2009 Feb 1;69(2):126-32. doi: 10.1002/pros.20865.

27.
28.

Mechanisms of selenium chemoprevention and therapy in prostate cancer.

Nadiminty N, Gao AC.

Mol Nutr Food Res. 2008 Nov;52(11):1247-60. doi: 10.1002/mnfr.200700369. Review.

PMID:
18727008
29.

Transcriptional regulation of human RANK ligand gene expression by E2F1.

Hu Y, Sun M, Nadiminty N, Lou W, Pinder E, Gao AC.

Biochem Biophys Res Commun. 2008 Jun 6;370(3):440-4. doi: 10.1016/j.bbrc.2008.03.106. Epub 2008 Mar 31.

30.

Development of an androgen-deprivation induced and androgen suppressed human prostate cancer cell line.

Lee SO, Dutt SS, Nadiminty N, Pinder E, Liao H, Gao AC.

Prostate. 2007 Sep 1;67(12):1293-300.

PMID:
17626246
31.

LIGHT, a member of the TNF superfamily, activates Stat3 mediated by NIK pathway.

Nadiminty N, Chun JY, Hu Y, Dutt S, Lin X, Gao AC.

Biochem Biophys Res Commun. 2007 Jul 27;359(2):379-84. Epub 2007 May 25.

33.

Stat3 activation of NF-{kappa}B p100 processing involves CBP/p300-mediated acetylation.

Nadiminty N, Lou W, Lee SO, Lin X, Trump DL, Gao AC.

Proc Natl Acad Sci U S A. 2006 May 9;103(19):7264-9. Epub 2006 May 1.

34.

Mechanisms of selenium down-regulation of androgen receptor signaling in prostate cancer.

Chun JY, Nadiminty N, Lee SO, Onate SA, Lou W, Gao AC.

Mol Cancer Ther. 2006 Apr;5(4):913-8.

35.
36.

Prostate-specific antigen modulates genes involved in bone remodeling and induces osteoblast differentiation of human osteosarcoma cell line SaOS-2.

Nadiminty N, Lou W, Lee SO, Mehraein-Ghomi F, Kirk JS, Conroy JM, Zhang H, Gao AC.

Clin Cancer Res. 2006 Mar 1;12(5):1420-30. Erratum in: Clin Cancer Res. 2006 Jun 1;12(11 Pt 1):3552.

37.

Selenium disrupts estrogen signaling by altering estrogen receptor expression and ligand binding in human breast cancer cells.

Lee SO, Nadiminty N, Wu XX, Lou W, Dong Y, Ip C, Onate SA, Gao AC.

Cancer Res. 2005 Apr 15;65(8):3487-92.

38.

Requirement for NF-(kappa)B in interleukin-4-induced androgen receptor activation in prostate cancer cells.

Lee SO, Lou W, Nadiminty N, Lin X, Gao AC.

Prostate. 2005 Jul 1;64(2):160-7.

PMID:
15678501
39.

Eugenol causes melanoma growth suppression through inhibition of E2F1 transcriptional activity.

Ghosh R, Nadiminty N, Fitzpatrick JE, Alworth WL, Slaga TJ, Kumar AP.

J Biol Chem. 2005 Feb 18;280(7):5812-9. Epub 2004 Dec 1.

Supplemental Content

Loading ...
Support Center